瑞珍斯生物 RGNX
$7.62 +$0.24 (+3.25%)
休市 · Nov 6, 10:00 pm ET · 最新盘后价 $7.62 0.00%
开盘$7.33
昨收$7.38
当日区间$7.33 – $7.87
成交量1.19M
市值$503.85M
市盈率（TTM）–
股息率–
财报
财报日平均波动±7.3%近16次财报
收涨次数6 / 1638% 的概率
最佳反应+18.7%
最差反应-37.8%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±15.2% | +7.43% | 符合区间 |
| 2026/Q1 | 14 May 2026 | Pre Market | ±32.4% | -37.80% | 超出定价预期 |
| 2025/Q4 | 5 Mar 2026 | Pre Market | ±38.1% | -4.60% | 符合区间 |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±33.1% | -3.79% | 符合区间 |
| 2025/Q2 | 7 Aug 2025 | Pre Market | – | -4.01% | – |
| 2025/Q1 | 12 May 2025 | After Market | ±18.6% | +2.63% | 符合区间 |
| 2024/Q4 | 13 Mar 2025 | After Market | ±31.2% | +2.60% | 符合区间 |
| 2024/Q3 | 6 Nov 2024 | After Market | ±21.2% | +18.66% | 符合区间 |
| 2024/Q2 | 1 Aug 2024 | After Market | ±23.5% | -2.03% | 符合区间 |
| 2024/Q1 | 8 May 2024 | After Market | ±17.8% | -5.94% | 符合区间 |
| 2023/Q4 | 27 Feb 2024 | After Market | ±17.5% | -0.60% | 符合区间 |
| 2023/Q3 | 8 Nov 2023 | After Market | ±13.1% | +2.44% | 符合区间 |
| 2023/Q2 | 2 Aug 2023 | After Market | ±14.4% | -7.51% | 符合区间 |
| 2023/Q1 | 3 May 2023 | After Market | ±13.0% | -1.58% | 符合区间 |
| 2022/Q4 | 28 Feb 2023 | Pre Market | ±14.3% | +1.41% | 符合区间 |
| 2022/Q3 | 3 Nov 2022 | Pre Market | ±16.8% | -13.16% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q2, ended Jun 2026
营收$108.02M+405.7% YoY
营业利润$29.26M+146.2% YoY
净利润$22.71M+132.0% YoY
摊薄每股收益$0.43+131.2% YoY
自由现金流-$63.00M-26.7% YoY
经营现金流-$62.24M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率86.4%
营业利润率-94.1%
净利率-112.6%
净资产收益率-137.6%
资产收益率-40.6%
投入资本回报率-71.5%
流动比率2.86
负债/资产比率81.4%
现金及投资$105.52M
总负债$61.60M
净现金（净负债）$43.92M
暂无评论——快来第一个聊聊 RGNX。
登录后参与讨论。